United States Patent Office Patented Aug
Total Page:16
File Type:pdf, Size:1020Kb
3,598,829 United States Patent Office Patented Aug. 10, 1971 2 3,598,829 The term lower alkyl is intended to include those hav CERTAIN SOXAZOLYLPYRONES AND ing 1 to 4 carbon atoms. The term halo is intended to SOTHAZOLYLPYRONES include chlorine, bromine, iodine and fluorine. Victor John Bauer, Montvale, and Sidney Robert Safir, e In general, the compounds are crystalline solids, soluble River Edge, N.J., assignors to American Cyanamid in Water. Company, Stamford, Conn. No Drawing. Continuation-in-part of application Ser. No. The compounds of the present invention may be pre 662,281, Aug. 22, 1967, which is a continuation-in-part pared by either of several general reaction sequences. of application Ser. No. 535,714, Mar. 21, 1966. This Thus, a 1-(4-pyridyl)-1,3-alkyldione or a 1-(4-pyridyl)- application Nov. 10, 1969, Ser. No. 875,524 1,3-alkyldione salt is reacted with a hydroxylamine salt int. C. C07d 31/48 O Such as the hydrochloride, in a polar solvent, such as U.S. C. 260-294.8D 9 Claims Water or alcohol, at a temperature of 25 to 100° C. for a time of one minute to twenty-four hours with or with out the addition of a base, such as sodium carbonate, to ABSTRACT OF THE DESCLOSURE provide either a 4-isoxazolylpyridine or a 1-(4-pyridyl)- 5 1,3-alkyldione oxime. When an oxime is formed, it is con This application describes the preparation of isoxazolyl Verted to a 4-isoxazolylpyridine by treatment with a de pyridines and isothiazolylpyridines as new compounds and hydrating agent, such as acetyl chloride or concentrated also their use in preparing the corresponding quaternary Sulfuric acid, at a temperature of 0 to 100° C. for a time isoxazolylpyridinium salts and quaternary isothiazolyl of one minute to twenty-four hours. Alternatively, an pyridinium salts. The quaternary isoxazolylpyridinium acetylene is allowed to react with a pyridine nitrile oxide, salts and quaternary isothiazolylpyridinium salts are use formed in situ from an isonicotinohydroxamyl chloride ful for their hypoglycemic activity. and triethylamine, to provide a 4-isoxazolylpyridine. For the Synthesis of isothiazolylpyridinium salts, and isoxa This application is a continuation-in-part of our appli Zolylpyridine is hydrogenated to provide an amino-pyr cation Ser. No. 662,281, filed Aug. 22, 1967, now U.S. 25 idyl-butenone, which is fused with phosphorus penta Pat. 3,511,848, which in turn is a continuation-in-part of Sulfide to provide an isothiazolylpyridine. our application Ser. No. 535,714, filed Mar. 21, 1966, These reactions are illustrated as follows: now abandoned. Method A PRIOR ART 30 Applicants are aware of British Pat. 875,887, directed R-éCH-5-( N or to pyridinium salts. However, the subject matter of the present application is not disclosed therein. R SUMMARY OF THE INVENTION QNa 9 NEOH.HCl 35 R-C-cCEIC- Y Nr. -, ( -- or This invention relates to new organic compounds. More SN- R1 particularly, it relates to isoxazolylpyridines and isothi R1 azolylpyridines, intermediates for preparation of quater NOH. O. NOH nary isoxazolylpyridinium salts and quaternary isothi azolylpyridinium salts. 40 The new compounds of the present invention may be illustrated by the following formula: R Nott S. R -41s. N. R-(-CH,-( N - 4 O Nz1 CD 45 ==/ N-1 R R1 R1 wherein R is selected from the group consisting of hydro gen, lower alkyl, and trihalo (lower) alkyl, R is selected RCCH2C-Not Y , R-4 ty Y from the group consisting of hydrogen and lower alkyl, No-1 k, Z is a trivalent radical selected from the group con 50 R1 sisting of Method B NOE h, $, N% -(-C) r-r-wlers =N -N - O Null and I Ri N R -S N^ so Resor;RC 4 YN and the dotted line represents one double bond, the posi 60 YN2 tion of which is dependent upon the definition of Z. When R1 R1 Z is Method C N / R -.) NH O NSo-1 N- (DN - R-(-CH- YN/ N R1 -- R NH O the double bond is adjacent to R and when Z has the 70 R-(-CH-)- N - N Y- S. other meanings, the double bond is adjacent to the pyr Ns 1 1 idinium ring. R1 R 3,598,829 4 Oral hypoglycemic activity is also observed in other species. For example, 1-methyl-4-(3-methyl-5-isoxazolyl)- pyridinium chloride, when administered to normal cock erels and guinea pigs causes a reduction in blood sugar levels. In addition, 1 - methyl-4-(3-methyl-5-isoxazolyl)- pyridinium chloride displays pronounced hypoglycemic activity in mice rendered experimentally hyperglycemic by an intravenous injection of alloxan. These results are recorded in Table II. O TABLE II.-ORAL HYPO GLYCEMIC ACTIVITY 1 OF1-METH YL-5-ISOXAZOLYL)PYRIDINIUM CELORIDE IN COCKER ELS, GUINEA PIGS AND ALLOXANIZED MICE wherein R and R1 are as hereinbefore defined. Time Percent The 4 - isoxazolylpyridines and 4-isothiazolylpyridines Dose, after reduction 2 are quaternized to 4-isoxazolylpyridinium salts and 4 Immolf dosing, in blood isothiazolylpyridinium salts by reaction with a lower alkyl, 5 Species and treatment kg. hrs. glucose lower alkenyl, cycloalkyl (lower) alkyl, or lower alkoxy Cockerels, drug (10)------------------ 1.99 2 343-47 Guinea pigs, saline (10), drug (6) ----- 5 6 13-2 (lower) alkyl halide at a temperature of 0 to 150 C. 354-6 with or without a solvent, such as alcohol, for a time Alloxanized mice, saline (28), drug (27). 0. 4 1-2 of one minute to twenty-four hours in an open vessel or 347-5 a sealed bomb. 20 i Cockerels and guinea pigs were fasted 24 hours before dosing. Food was withheld from all animals after dosings. Among the compounds of the present invention, are, 2 Values are means == SE. of number of animals indicated in parentheses for example, 4-(3-methyl - 5 - isoxazolyl)pyridine, 4-(3- and are expressed as percent reduction from predose levels or from Saline control in the case of cockerels (blood glucose of 10 saliane control cockerels ethyl - 5 - isoxazolyl)pyridine, 4 - (3 - cyclopropyl-5- was 143als 5 mg. percent). isoxazolyl)pyridine, 4 - (3 - trifluoromethyl-5-isoxazolyl) 3 Significantly different from control. pyridine, 4 - (5 - trifluoromethyl - 3 - isoxazolyl)pyridine, 25 These results show that the compounds prepared from 4 - (5 - isoxazolyl)pyridine, 4 - (5 - methyl-3-isoxazolyl) the intermediates of the present invention are useful in pyridine, 3 - methyl - 4 - (3 - methyl - 5 - isoxazolyl)pyr the lowering of blood glucose in normal and hypergly idine, 4 - (5 - methyl - 3 - isothiazolyl)pyridine and 4-(3- cemic warm-blooded animals. methyl-5-isothiazolyl)pyridine. The compounds prepared from the intermediates of this The compounds directly prepared from the intermedi 30 invention can be used in compositions such as tablets; the ates of the present invention show hypoglycemic activity principal active ingredient is mixed with conventional based on the following data which shows a reduction in tableting ingredients such as corn starch, lactose, sucrose, blood sugar levels in mice, guinea pigs and cockerels. Sorbitol, talc, Stearic acid, magnesium stearate, dicalcium When the compounds are administered orally to normal phosphate, gums, and fractionally similar materials as mice, a reduction of blood sugar levels is observed. Mice pharmaceutical diluents or carriers. The tablets or pills used in these studies are MF-1 (Manor Farms, 18-25 of the novel compositions can be laminated or otherwise grams). The compounds are administered by gavage as compounded to provide a dosage form affording the ad saline solutions. Control animals receive an equivalent vantage of prolonged or delayed action or predetermined volume of vehicle. Food is withheld from animals after Successive action of the enclosed medication. For ex dosing. Blood glucose is determined 2 to 6 hours after 40 ample, the tablet or pill can comprise an inner dosage and dosing by the method of Hoffman J. Biol. Chem., 120, an Outer dosage component, the latter being in the form 51 (1937) as adapted to the Technicon AutoAnalyzer® of an envelope over the former. The two components can and is expressed as percent change from saline controls. be separated by an enteric layer which serves to resist Blood samples are obtained from the tail veins of mice. disintegration in the stomach and permits the inner com The testing data is summarized in Table I. 45 ponent to pass intact into the duodenum or to be delayed TABLE I.--DECREASE IN BLOOD GLUCOSE IN NORMAL, MICE, AFTER, ORAL ADMINIS TRATION OF SOXAZOLYLEPYRIDINIUM SALTS Percent decrease in blood glucose, dose, Hours Eng./kg. after Compound dosing 25 250 500 1-methyl-4-(3-methyl-5-isoxazolyl)pyridinium chloride 36-5 08 695 1-methyl-4-(3-ethyl-5-isoxazolyl)pyridinium chloride 243 4-7 637 1-allyl-4-(3-methyl-5-isoxazolyl)pyridinium chloride -9 98 39-14 1-methyl-4-(5-isoxazolyl)pyridinium chloride----- 2 24.4 6 10.6 24.2 48 25.2 34-3 07 2. 1,3-dimethyl-4-(3-methyl-5-isoxazolyl)pyridinium chloride.------------- 2 122 277 304 k 1410 36-13 768 All 2-3 763 1-(2-methoxyethyl)-4-(3-methyl-5-isoxazolyl)pyridinium chloride------ 8-7 263 30-7 t as 7 5-6 31.13 9 97 221 -methyl-4-(5-trifluoromethyl-3-isoxazolyl)pyridinium chloride-------- 7 E72 68 116 344 29 1-methyl-4-(5-methyl-3-isoxazolyl)pyridinium chloride----------------- 2 El5 30-9 144 0-4 578 53-li 1-cyclopropylmethyl-4-(3-methyl-5-isoxazolyl)pyridinium bromide...-- -80 10-8 10-5 -2011 E09 11-6 i-ethyl-4-(3-methyl-5-isoxazolyl)pyridinium iodide--------------------- 2 0-2 146 3-4 4 ---------- 165 20-7 1-ethyl-4-(3-ethyl-5-isoxazolyl)-pyridinium iodide...-------------------- 22:-4 5-5 24 t 307 320 385 1-propyl-4-(3-methyl-5-isoxazolyl)-pyridinium bromide---------------- 2 -52 163 223 4 54 35 75 1-methyl-4-(3-methyl-5-isoxazolyl)-pyridinium iodide------------------ 5 13-3 is 359 40-9 1-methyl-4-(5-methyl-3-isoxazolyl)-pyridinium iodide--- 3 562-12 93-1 ---------- Values are means standard errors of 4 to 8 mice per dose and are expressed as percent decrease from predose walues.